Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melanie Calvert

Showing results (201-210 of 222) with videos related to

Pageof 23
Sort By:
Nature Medicine|March 18, 2023
Patient and public involvement within epidemiological studies of long COVID in the UKAsh Routen, Lauren O'Mahoney, Olalekan Lee Aiyegbusi, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 13, 2026
Kidney disease increases the risk of cardiovascular events in patients with device-detected atrial fibrillation: NOAH-AFNET 6Andreas Goette, Marc D Lemoine, Alexander Fierenz, et al.
Eclinicalmedicine|October 10, 2024
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtableChristina Yap, Olalekan Lee Aiyegbusi, Emily Alger, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 1, 2025
Effects of anticoagulation in patients with device-detected atrial fibrillation and multiple stroke risk factors: a win ratio analysis of the NOAH-AFNET 6 trialNina Becher, Gina Köllner, Emanuele Bertaglia, et al.
Journal of the American Heart Association|August 27, 2024
Anticoagulation in Patients With Device-Detected Atrial Fibrillation With and Without a Prior Stroke or Transient Ischemic Attack: The NOAH-AFNET 6 TrialHans Christoph Diener, Nina Becher, Susanne Sehner, et al.
The New England Journal of Medicine|August 25, 2023
Anticoagulation with Edoxaban in Patients with Atrial High-Rate EpisodesPaulus Kirchhof, Tobias Toennis, Andreas Goette, et al.
JAMA|February 8, 2018
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO ExtensionMelanie Calvert, Derek Kyte, Rebecca Mercieca-Bebber, et al.
European Heart Journal|April 9, 2024
Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trialGregory Y H Lip, Julius Nikorowitsch, Susanne Sehner, et al.
BMJ (Clinical Research Ed.)|October 20, 2023
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidanceChristina Yap, Olga Solovyeva, Johann de Bono, et al.
European Heart Journal|November 13, 2023
Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 hNina Becher, Tobias Toennis, Emanuele Bertaglia, et al.
Pageof 23

Showing results (201-210 of 222) with videos related to

Sort By:
Pageof 23
Nature Medicine|March 18, 2023
Patient and public involvement within epidemiological studies of long COVID in the UKAsh Routen, Lauren O'Mahoney, Olalekan Lee Aiyegbusi, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 13, 2026
Kidney disease increases the risk of cardiovascular events in patients with device-detected atrial fibrillation: NOAH-AFNET 6Andreas Goette, Marc D Lemoine, Alexander Fierenz, et al.
Eclinicalmedicine|October 10, 2024
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtableChristina Yap, Olalekan Lee Aiyegbusi, Emily Alger, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 1, 2025
Effects of anticoagulation in patients with device-detected atrial fibrillation and multiple stroke risk factors: a win ratio analysis of the NOAH-AFNET 6 trialNina Becher, Gina Köllner, Emanuele Bertaglia, et al.
Journal of the American Heart Association|August 27, 2024
Anticoagulation in Patients With Device-Detected Atrial Fibrillation With and Without a Prior Stroke or Transient Ischemic Attack: The NOAH-AFNET 6 TrialHans Christoph Diener, Nina Becher, Susanne Sehner, et al.
The New England Journal of Medicine|August 25, 2023
Anticoagulation with Edoxaban in Patients with Atrial High-Rate EpisodesPaulus Kirchhof, Tobias Toennis, Andreas Goette, et al.
JAMA|February 8, 2018
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO ExtensionMelanie Calvert, Derek Kyte, Rebecca Mercieca-Bebber, et al.
European Heart Journal|April 9, 2024
Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trialGregory Y H Lip, Julius Nikorowitsch, Susanne Sehner, et al.
BMJ (Clinical Research Ed.)|October 20, 2023
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidanceChristina Yap, Olga Solovyeva, Johann de Bono, et al.
European Heart Journal|November 13, 2023
Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 hNina Becher, Tobias Toennis, Emanuele Bertaglia, et al.
Pageof 23